No association between low-dose reserpine use and depression in older hypertensive patient: result of a multicenter, cross-sectional study
Guo-Hua ZHU
Xi-Peng SUN
Jing LI
Lin PI
Hai-Qin TANG
Hai-Qing GAO
Hong-Liang CONG
Peng QU
Xin-Zheng LU
Xin-Jun ZHANG
Luo-Sha ZHAO
Yi-Fang GUO
Dong-Xia LIU
Liang-Qing ZHANG
Hua TANG
Yi-Xin HU
Li FAN
Qi HUA
摘要：Background Reserpine is currently used by millions of Chinese hypertensive patients,in spite of the continued concem of its depressogenic effect,even when used in low dose.This study aimed to investigate the association between low-dose reserpine use and depression in older Chinese hypertensive patient.Methods In this cross-sectional,case-control study,we recruited patient aged 60 years or over who had regularly taken one or two tables of"compound reserpine and triamterene tablets (CRTTs)" for more than one year (reserpine user) from 26 community health centers located in 10 provinces in China.For each patient who took CRTTs,we selected an age (within five years) and sex matched hypertensive patient who had never taken any drugs containing reserpine (non-reserpine user) as control.Depressive symptoms were evaluated using a Chinese depression scale adapted from the Zung Self-Rating Depression Scale.Demographic,clinical data and laboratory examination results within six months were collected.Results From August 2018 to December 2018,787 reserpine user and 787 non-reserpine user were recruited.The mean age of all study subjects was 70.3 years,with about equal numbers of males and females.The mean depression score was 40.4 in reserpine users and 40.6 in non-reserpine users (P =0.7).The majority of study subject had a depression score ＜ 53 (87.6％ in reserpine users and 88.2％ in non-reserpine users,respectively).There were no significant differences in the prevalence of mild,moderate or severe depression in reserpine users and non-reserpine users.Conclusions There is no association between low-dose reserpine use and depression in older hypertensive patient.The role of reserpine in the treatment and control of hypertension should be reconsidered;and further studies,especially randomized,controlled clinical trials to compare efficacy and safety of reserpine and other widely recommended anti-hypertensive agents are needed.
机标关键词：
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：6( 608-613 )
英文信息